Hsing-Mao Chu
Chief Executive Officer T-E Meds
Hsing-Mao Chu received his Ph.D. degree from National Taiwan University in 2010, studying protein-ligand interactions at atomic resolution using x-ray crystallography. He joined Dr. Tse-Wen Chang’s team in the Genomics Research Center, Academia Sinica, in 2011 to study CemX on human mIgE and develop anti-CemX antibodies for depleting IgE-expressing B cell. After 2013, his work expanded to antibody engineering and bioconjugation for developing therapeutic multi-specific antibodies.
In 2015, he joined Immunwork as Director of R&D and was promoted to Vice President of R&D in 2019. He leads a dynamic team focused on developing ADCs, antibody-radionuclide conjugates (ARCs), and fatty acid (FA) bundle-modified peptides. Through the team’s collaborative efforts, two remarkable ultra-long-acting peptide drugs initiated their first-in-human trials in the first half of 2024. These include a FA bundle-modified GLP-1 receptor agonist and a FA bundle-modified octreotide analogue. In 2023, he became the CEO of T-E Meds, Inc., a sister company of Immunwork, dedicated to advancing ADC and ARC platforms and related products. Dr. Chu is a co-inventor on more than 70 granted patents.
Seminars
- Enabling flexible 2- or 4-site conjugation per antibody to allow precise control of payload ratios and combinations to develop mono or dual payload ADCs
- Explaining how one integrated Drug Bundle conjugation process supports diverse ADC modalities through cysteine/thiol–maleimide conjugation and glycan-specific or MTGase-enabled click conjugation
- Exploring how Drug Bundle-based ADCs have the potential to enhance stability and efficacy while helping overcome drug resistance
